Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19.
Mateo-Urdiales A, Sacco C, Petrone D, Bella A, Riccardo F, Del Manso M, Bressi M, Siddu A, Brusaferro S, Palamara AT, Rezza G, Pezzotti P, Fabiani M; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Mateo-Urdiales A, et al. JAMA Netw Open. 2023 Oct 2;6(10):e2336854. doi: 10.1001/jamanetworkopen.2023.36854. JAMA Netw Open. 2023. PMID: 37792377 Free PMC article.
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study.
Fabiani M, Puopolo M, Morciano C, Spuri M, Spila Alegiani S, Filia A, D'Ancona F, Del Manso M, Riccardo F, Tallon M, Proietti V, Sacco C, Massari M, Da Cas R, Mateo-Urdiales A, Siddu A, Battilomo S, Bella A, Palamara AT, Popoli P, Brusaferro S, Rezza G, Menniti Ippolito F, Pezzotti P; Italian Integrated Surveillance of covid-19 study group and Italian covid-19 Vaccines Registry group. Fabiani M, et al. BMJ. 2022 Feb 10;376:e069052. doi: 10.1136/bmj-2021-069052. BMJ. 2022. PMID: 35144968 Free PMC article.
Envelope-dimer epitope-like broadly protective antibodies against dengue in children following natural infection and vaccination.
Mpingabo PI, Ylade M, Aogo RA, Crisostomo MV, Thiono DJ, Daag JV, Agrupis KA, Escoto AC, Raimundi-Rodriguez GL, Odio CD, Fernandez MA, White L, de Silva AM, Deen J, Katzelnick LC. Mpingabo PI, et al. Among authors: odio cd. medRxiv [Preprint]. 2024 May 1:2024.04.30.24306574. doi: 10.1101/2024.04.30.24306574. medRxiv. 2024. PMID: 38746253 Free PMC article. Preprint.
Dengue virus IgG and serotype-specific neutralizing antibody titers measured with standard and mature viruses are associated with protection.
Katzelnick L, Odio C, Daag J, Crisostomo MV, Voirin C, Escoto AC, Adams C, Hein LD, Aogo R, Mpingabo P, Rodriguez GR, Firdous S, Fernandez MA, White L, Agrupis KA, Deen J, de Silva A, Ylade M. Katzelnick L, et al. Among authors: odio c. Res Sq [Preprint]. 2024 Apr 12:rs.3.rs-4145863. doi: 10.21203/rs.3.rs-4145863/v1. Res Sq. 2024. PMID: 38659845 Free PMC article. Preprint.
Severe dengue progression beyond enhancement.
Odio CD, Aogo RA, Lowman KE, Katzelnick LC. Odio CD, et al. Nat Immunol. 2023 Dec;24(12):1967-1969. doi: 10.1038/s41590-023-01680-1. Nat Immunol. 2023. PMID: 38012410 No abstract available.
Phase 1 trial to model primary, secondary, and tertiary dengue using a monovalent vaccine.
Odio CD, Lowman KE, Law M, Aogo RA, Hunsberger S, Wood BJ, Kassin M, Levy E, Callier V, Firdous S, Hasund CM, Voirin C, Kattappuram R, Yek C, Manning J, Durbin A, Whitehead SS, Katzelnick LC. Odio CD, et al. BMC Infect Dis. 2023 May 23;23(1):345. doi: 10.1186/s12879-023-08299-5. BMC Infect Dis. 2023. PMID: 37221466 Free PMC article. Clinical Trial.
63 results